The next edition of earnings season begins in earnest next Wednesday morning, with three of the nation’s biggest banks releasing fiscal first-quarter results before the opening bell is rung.
In the meantime, we have two earnings reports due before markets open Monday, one for a marijuana grower and the other a distributor of industrial supplies.
[in-text-ad]
Fastenal
Fastenal Co. (NASDAQ: FAST) is a wholesale distributor of industrial and construction supplies like bolts, nuts and washers to a wide range of markets. The stock added nearly 37% to its share price last year and posted its 52-week high in mid-January. So far in 2021, the stock has added just over 2%.
Analysts have a consensus price target of $50.63 on the stock with half (nine) rating the shares a Hold and the other nine rate the stock as a Buy or Strong Buy. At its current trading price of around $49.50, the potential upside on the stock is about 2.3%.
The consensus estimate for 2021 first-quarter earnings per share (EPS) is $0.37, an increase of two cents compared with the prior-year quarter. Revenue is forecast to reach $1.43 billion, a year-over-year increase of 4.8%. Current estimates for full-year EPS and revenue are $1.56 (up 4.7%) and $5.9 billion (up 4.4%), respectively. Fastenal raised its quarterly dividend by 12% to $0.28 per share ($1.12 annualized) in January.
The shares traded down about 1.4% in the noon hour Friday, at $49.53 in a 52-week range of $31.87 to $51.89. At the current trading price, the stock trades at 32.0 times expected 2021 EPS, 29.0 times expected 2022 earnings and 26.5 times expected 2023 earnings.
OrganiGram
OrganiGram Holdings Inc. (NASDAQ: OGI) is a Canadian company that grows marijuana and manufactures and sells a range of cannabis and cannabis-derived products in Canada. The company’s stock dropped nearly 46% last year and added about 35% in 2021 through early February, before dropping about half that gain and settling Thursday with a year-to-date gain of 140%. That’s good enough for a 12-month share-price gain of nearly 75%.
At a recent trading price of around C$4.00, the stock has outrun its average price target of C$2.76, likely due to its identification as a meme stock along with GameStop and AMC Entertainment. That’s not an entirely accurate take, however, because OrganiGram’s shares trade at a multiple of about 13 times expected sales for 2021, not an unrealistically high multiple given Canopy Growth’s multiple of nearly 39.
Analysts are expecting the company to post a net loss per share for the February quarter of C$0.03 in the quarter, equal to its year-ago loss. Revenue is forecast at C$19.8 million, down from C$25 million in the year-ago quarter.
Shares traded down about 0.5% Friday to C$3.95, in a 52-week range of C$1.35 to C$8.00. OrganiGram is not expected to post a profit for either the 2021 or 2022 fiscal years.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.